Celecoxib in Colposcopic Directed Biopsy

• Status: Completed
• Trial end date: 2019-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

Women often experience pain and discomfort during colposcopic examination especially at time of colposcopic directed excisional biopsy, pre-procedure anxiety, women pain threshold may also increase pain, woman's cooperation during the procedure is affected by all these factors, which also may hinder the colposcopist from obtaining adequate data and biopsies.

Several pharmacological and non-pharmacological methods have been studied to reduce pain associated colposcopic directed biopsy (CDB). We aim to study the effect of Celecoxib to reduce pain associated with CDB.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• Females 18-65 years old who undergoing colposcopic directed biopsy

Exclusion Criteria:

• A known allergy to Celecoxib, aspirin or another NSAID.

• Active peptic ulceration or gastrointestinal bleeding.

• Inflammatory bowel disease.

• Congestive heart failure (NYHA II-IV).

• Established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

• History of neurologic deficit.

• Known hepatic or renal impairment.

• Pregnancy.

• Breast-feeding.

• Post-hysterectomy.

• Bleeding disorders.

• Drug abuse.

• Cervical and vaginal infection.